Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Preclinical debut
May 2019
SHARING OPTIONS:

CAMBRIDGE, Mass.—Clinical-stage company Jounce Therapeutics Inc. shared preclinical data at the recent 2019 American Association for Cancer Research Annual Meeting regarding its first tumor-associated macrophage program, JTX-8064. The compound is a specific, potent antagonist antibody of LILRB2 (leukocyte immunoglobulin-like receptor B2, ILT4), which binds to its ligands and maintains an immuno-suppressive state in macrophages. By blocking ligand binding to LILRB2, it’s thought that JTX-8064 triggers an immune-activating state in macrophages, a reprogramming that could help to enhance the anti-tumor immune response. Jounce Therapeutics intends to file an Investigational New Drug application and launch a Phase 1 clinical trial for the program this year.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.